Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Company Announcement COPENHAGEN, Denmark; May 17, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
-
Company Announcement COPENHAGEN, Denmark; May 12, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
-
Company Announcement COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
-
Company Announcement COPENHAGEN, Denmark; May 11, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,418 shares as a consequence of the exercise of employee warrants. The...
-
Company Announcement COPENHAGEN, Denmark; May 10, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
-
Company Announcement COPENHAGEN, Denmark; May 07, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this...
-
May 5, 2021; Copenhagen, Denmark; Genmab Interim Report for the First Quarter Ended March 31, 2021 Highlights Genmab and Seagen Inc. submitted tisotumab vedotin Biologics License Application...
-
Company Announcement COPENHAGEN, Denmark; May 03, 2021 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
-
Company Announcement COPENHAGEN, Denmark; May 3, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
-
Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from...